[Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer].
Hernádi
Z
Z
Juhász
B
B
Póka
R
R
Mahunka
I
I
Lampé
L
L
D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010440:Peptichemio / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation
D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio
A CAP és CEP gyógyszerkombinációk hatékonyságának és mellékhatásainak vizsgálata elörehaladott stádiumú petefészekrákos betegek kezelése során.